Phase Ib / II Trial Evaluating the Association Myocet - Carboplatine in Patients Having a Cancer of the Ovary in Relapse, Sensitive to the Platinum

Trial Profile

Phase Ib / II Trial Evaluating the Association Myocet - Carboplatine in Patients Having a Cancer of the Ovary in Relapse, Sensitive to the Platinum

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Carboplatin
  • Indications Ovarian cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms Gineco; MYCA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Status changed from active, no longer recruiting to completed according to the results presented at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top